NCT02641639 2025-03-24
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
Mateon Therapeutics
Phase 2/3 Terminated
Mateon Therapeutics
Seoul National University Hospital
University Hospital, Linkoeping
Ciusss de L'Est de l'Île de Montréal
Masonic Cancer Center, University of Minnesota
University of California, San Francisco